Free Newsletter
Countries report flu vaccine inventory
The chief medical officer from Down Under says supplies of the three-in-one seasonal flu shot are running low due to delays in manufacturing and delivery. But there's no shortage for the high-risk and indigenous Australians who qualify for a free program. Swine flu vaccine, by contrast, is plentiful; less than half of the 21-million-dose inventory is being used.
In India, Cadila Healthcare now boasts the first indigenously made H1N1 vaccine. The egg-based, inactivated prophylactic is made via a platform that can be used to produce any pandemic influenza vaccine in addition to seasonal flu vaccine, says a local press report. In addition, two other drugmakers have H1N1 vaccines in the works, with launch in India expected in the next few months.
And in Kathmandu, officials say they anticipate the first H1N1 vaccine shipment--2.7 million doses, for ten percent of Nepal's population--in September. Under a WHO program, Nepal was slated to receive the vaccine by March. But manufacturing delays and minimal flu spread led the government to postpone imports for six months.
- here's the Australia story
- see the report from India
- read this report from Nepal
Related Articles:
H1N1 vax largely unused, almost expired
Vaccine demand plunges as H1N1 pandemic fears fade
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

SHARE
WITH: